Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q1 2019 · 10-Q
Revenue$41.55K$41.55Kno prior Q1 2018 on file Net Income$53.96K$53.96KN/M vs Q1 2018 EPS Diluted$0.00$0.00N/M vs Q1 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Operating Cash Flow-$72,833N/M Margins · derivedGross margin77.7%
Operating margin-406.4%
Net margin129.9%
ended Mar 31, 2019 · filed Apr 19, 2019 · 19 d after period end